Clinical trials
Alzheimer's Disease Diagnosis clinical trials
Below are recruiting alzheimer's disease diagnosis clinical trials, each written for real people, not researchers. We’re tracking 300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06781333RecruitingPhase 2
Stem cells for behavior problems in Alzheimer's
This trial tests whether a single infusion of human mesenchymal stem cells (hMSC) can improve difficult behaviors like agitation, anxiety, or hallucinations in people with Alzheimer's disease. It's designed for those who have been taking antipsychotic medication for at least 4 weeks and have a study partner to help track behavior changes.
Miami, FloridaAges 55–90 - NCT06841848Recruiting
Eye camera test for early Alzheimer's
This study is testing a new eye camera to see if it can help find early signs of Alzheimer's disease. It is for people aged 55 and older who either have mild to moderate Alzheimer's or do not have Alzheimer's.
Rome, ItalyAges 55 years+ - NCT06883019Recruiting
Lecanemab for early onset inherited Alzheimer's
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Beijing, ChinaAges 18–65 - NCT06936124Recruiting
Deep brain stimulation for Alzheimer's disease
This trial tests whether deep brain stimulation of a specific brain area can help people with Alzheimer's disease. It aims to see if this treatment can improve symptoms and quality of life.
Toronto, OntarioAges 60 years+ - NCT06995573RecruitingPhase 1/Phase 2
Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Salzburg, State of SalzburgAges 50–85 - NCT07058688RecruitingPhase 2
Testing a new drug for Alzheimer's (NTRX-07)
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
BrnoAges 65–80 - NCT07127510Recruiting
Brain NAD in Alzheimer's disease study
This study tests whether a natural substance called NAD can improve brain health in people with early Alzheimer's. You may be eligible if you have a firm Alzheimer's diagnosis, are between 65 and 80, and can walk and talk without help.
Boca Raton, FloridaAges 65–80 - NCT07142954RecruitingPhase 3
Alzheimer's research study for healthy people
This study is looking at healthy people with no memory concerns to better understand early signs of Alzheimer's disease. You would provide samples and do thinking tests, but you won't take any experimental medicines.
Houston, TexasAges 55–75 - NCT07213349RecruitingPhase 2
Daridorexant for Alzheimer's prevention
This study tests whether daridorexant, a medication that helps improve sleep, can prevent Alzheimer's disease. If you have mild memory concerns but not dementia, this trial may help find out if better sleep can protect your brain.
Montreal, QuebecAges 50–90 - NCT07328451RecruitingPhase 1
Study of DNL628 for people with early Alzheimer's disease
This trial tests an experimental drug, DNL628, to see if it is safe and how it affects people with early Alzheimer's disease. It may help slow the disease by targeting a specific process in the brain.
's-HertogenboschAges 18–75 - NCT07545473Recruiting
Eye Imaging to Detect Brain Disease Markers
This study uses a special camera to photograph the back of your eye in detail. Researchers believe changes in the eye may reflect brain diseases like Alzheimer's or Parkinson's, and this imaging could help detect these conditions earlier.
Melbourne, VictoriaAges 30 years+ - NCT07543094Enrolling by invitation
Brain Stimulation for Early Alzheimer's Memory and Thinking
This study tests whether a special type of brain stimulation called temporal interference stimulation can improve memory and thinking skills in people with early-stage Alzheimer's disease. The treatment uses electrical stimulation to target specific brain areas without surgery.
Shanghai, Shanghai MunicipalityAges 50–75 - NCT06963879Enrolling by invitation
Video game test and treatment for Alzheimer's disease
This study uses interactive video games to help diagnose and potentially treat early-stage Alzheimer's disease or mild cognitive impairment. It is testing whether these games can improve thinking skills.
Mataró, BarcelonaAges 50 years+ - NCT03019757Recruiting
Testing ways to tell dementia causes apart
This study looks at how to distinguish Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease when someone has memory and thinking problems. It may help doctors choose the most accurate diagnosis and treatment path for the right condition.
Columbus, OhioAges 18 years+ - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT07632755Recruiting
Memory Training Using Movement for Early Alzheimer's Disease
This study tests whether learning memory strategies through physical movement and motor activities can help people with early Alzheimer's disease improve their memory. Researchers will compare people with early Alzheimer's to healthy older adults to see if this approach is effective.
GrenobleAges 60 years+ - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Chandler, ArizonaAges 55–90 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Miami, FloridaAges 50 years+ - NCT05020106Recruiting
Tests Alzheimer’s core blood/brain markers to set diagnostic cutoffs
This study checks Alzheimer’s “core biomarkers” to find the best cut-off values for diagnosing Alzheimer’s disease and related conditions. It may help doctors more accurately tell Alzheimer’s, mild cognitive changes, and other causes of memory problems apart.
Beijing, Beijing MunicipalityAges 55–75 - NCT05059158Recruiting
Study how the brain clears amyloid in Alzheimer’s
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
München, BavariaAges 50–85 - NCT05205980Recruiting
Training practice to help prevent falls in Alzheimer’s
This trial tests whether a specific “training practice” can reduce falls in people with probable Alzheimer’s disease. It may help by improving safe walking and balance after doing the training.
Valdosta, GeorgiaAges 65–90 - NCT05908695RecruitingPhase 4
GV-971 treatment for mild to moderate Alzheimer’s disease
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Huainan, AnhuiAges 50–85
Hear when a new Alzheimer's Disease Diagnosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer's disease diagnosis?
- Yes. Clin2 currently lists 300 recruiting alzheimer's disease diagnosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer's disease diagnosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer's disease diagnosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.